Athira Pharma, Inc. Common Stock
ATHA US04746L1044
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -56% | -76% | -28% | -80% | 4% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Worthington Mark CCO |
0.29 USD |
8,526 Sold |
2,502 USD |
30/06/2025 | 01/07/2025 |
| Renninger Robert CCO |
0.29 USD |
2,897 Sold |
850 USD |
30/06/2025 | 01/07/2025 |
| Litton Mark James CEO |
0.29 USD |
25,123 Sold |
7,374 USD |
30/06/2025 | 01/07/2025 |
| Church Kevin SR OFF |
0.29 USD |
8,526 Sold |
2,502 USD |
30/06/2025 | 01/07/2025 |
| San Martin Javier CMO |
0.29 USD |
10,842 Sold |
3,182 USD |
30/06/2025 | 01/07/2025 |
| San Martin Javier CMO |
0.56 USD |
10,826 Sold |
6,083 USD |
31/12/2024 | 02/01/2025 |
| Litton Mark James CEO |
0.56 USD |
25,107 Sold |
14,108 USD |
31/12/2024 | 02/01/2025 |
| Church Kevin SR OFF |
0.56 USD |
8,510 Sold |
4,782 USD |
31/12/2024 | 02/01/2025 |
| Renninger Robert VP |
0.56 USD |
2,881 Sold |
1,619 USD |
31/12/2024 | 02/01/2025 |
| Worthington Mark CCO |
0.56 USD |
8,510 Sold |
4,782 USD |
31/12/2024 | 02/01/2025 |